Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SRTS Stock Forecast 2026-2027
$4.44
Current Price
$73.09M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SRTS Price Targets
+80.2%
To High Target of $8.00
+52.0%
To Median Target of $6.75
+35.1%
To Low Target of $6.00
SRTS Price Momentum
-1.1%
1 Week Change
+13.6%
1 Month Change
-3.3%
1 Year Change
+11.6%
Year-to-Date Change
-25.0%
From 52W High of $5.92
+46.5%
From 52W Low of $3.03
📊 TOP ANALYST CALLS
Did SRTS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Sensus Healthcare is one of their latest high-conviction picks.
Latest SRTS Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, SRTS has a bullish consensus with a median price target of $6.75 (ranging from $6.00 to $8.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $4.44, the median forecast implies a 52.0% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yi Chen at HC Wainwright & Co., projecting a 80.2% upside. Conversely, the most conservative target is provided by Anthony Vendetti at Maxim Group, suggesting a 35.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SRTS Analyst Ratings
4
Buy
0
Hold
0
Sell
SRTS Price Target Range
Low
$6.00
Average
$6.75
High
$8.00
Current: $4.44
Latest SRTS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SRTS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 17, 2026 | Maxim Group | Anthony Vendetti | Buy | Maintains | $6.00 |
| Aug 12, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $8.00 |
| Aug 8, 2025 | Lake Street | Ben Haynor | Buy | Maintains | $6.00 |
| May 19, 2025 | Maxim Group | Anthony Vendetti | Buy | Maintains | $10.00 |
| Apr 4, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $12.00 |
| Mar 11, 2025 | Lake Street | Ben Haynor | Buy | Maintains | $13.00 |
| Feb 10, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $12.00 |
| Nov 18, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $11.00 |
| Nov 15, 2024 | Maxim Group | Anthony Vendetti | Buy | Maintains | $14.00 |
| Aug 12, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $10.00 |
| May 13, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $10.00 |
| May 10, 2024 | Maxim Group | Anthony Vendetti | Buy | Maintains | $10.00 |
| Nov 13, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $8.00 |
| Aug 7, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $8.00 |
| May 4, 2023 | Alliance Global Partners | Ben Haynor | Buy | Maintains | $7.00 |
| May 4, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $10.00 |
| Feb 10, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $16.00 |
| Feb 10, 2023 | Alliance Global Partners | Ben Haynor | Buy | Maintains | $14.50 |
| Nov 4, 2022 | Alliance Global Partners | Ben Haynor | Buy | Maintains | $16.50 |
| May 6, 2022 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $16.00 |
Sensus Healthcare Inc. (SRTS) Competitors
The following stocks are similar to Sensus Healthcare based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SRTS
Sensus Healthcare
mkt cap
73.91M
Sensus Healthcare Inc. (SRTS) Financial Data
Sensus Healthcare Inc. has a market capitalization of $73.09M with a P/E ratio of 49.5x. The company generates $27.48M in trailing twelve-month revenue with a -28.1% profit margin.
Revenue growth is -62.2% quarter-over-quarter, while maintaining an operating margin of -63.7% and return on equity of -14.9%.
Valuation Metrics
Market Cap
$73.09M
Enterprise Value
$52.30M
P/E Ratio
49.5x
PEG Ratio
-0.2x
Price/Sales
2.7x
Growth & Margins
Revenue Growth (YoY)
-62.2%
Gross Margin
+38.4%
Operating Margin
-63.7%
Net Margin
-28.1%
EPS Growth
-62.2%
Financial Health
Cash/Price Ratio
+30.2%
Current Ratio
9.7x
Debt/Equity
1.0x
ROE
-14.9%
ROA
-11.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Sensus Healthcare Inc. (SRTS) Business Model
About Sensus Healthcare Inc.
What They Do
Develops non-invasive medical treatment technologies.
Business Model
Sensus Healthcare generates revenue by selling its mobile superficial radiation therapy systems, such as the SRT-100, to dermatologists, oncologists, and healthcare facilities. By focusing on non-surgical treatments for conditions like non-melanoma skin cancers and keloids, the company positions itself in a niche market that prioritizes patient comfort and reduced recovery times.
Additional Information
Founded in the early 2000s, Sensus Healthcare primarily operates in the U.S. but is expanding internationally. The company addresses growing market demands for efficient and minimally invasive medical solutions, which can lead to cost savings for patients and healthcare providers alike.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
60
CEO
Mr. Joseph C. Sardano
Country
United States
IPO Year
2016
Website
sensushealthcare.comSensus Healthcare Inc. (SRTS) Latest News & Analysis
Latest News
Quick Summary
Sensus Healthcare, Inc. has filed a lawsuit against SkinCure Oncology for breach of contract over unpaid amounts owed. The case is in the Circuit Court in Palm Beach County, Florida.
Why It Matters
The lawsuit against SkinCure could impact Sensus Healthcare's financial performance and stock price, highlighting potential revenue risks and legal uncertainties.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Sensus Healthcare (Nasdaq: SRTS) launched Sensus Link, a cloud-based software to enhance the capabilities of its SRT-100™ system for treating skin conditions.
Why It Matters
Sensus Healthcare's introduction of Sensus Link enhances its SRT-100 system, potentially boosting operational efficiency and patient outcomes, which could drive revenue growth and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Sensus Launches Sensus Healthcare Financial Services to Facilitate Customer Acquisition of SRT Technology
1 month ago
Quick Summary
Sensus Healthcare (Nasdaq: SRTS) launched Sensus Healthcare Financial Services to facilitate dermatology practices in acquiring their superficial radiotherapy systems with a streamlined financing process.
Why It Matters
Sensus Healthcare's new financial services program could increase sales of its SRT systems by making them more accessible to dermatology practices, potentially boosting revenue and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Sensus Healthcare, Inc. (SRTS) held its Q4 2025 earnings call, discussing financial performance and strategic outlook. Further details can be found in the full transcript.
Why It Matters
The earnings call provides insights into Sensus Healthcare's financial performance, growth prospects, and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Sensus Healthcare, Inc. reported Q4 revenues of $4.9 million and full-year revenues of $27.5 million, with a net loss of $3.2 million for the quarter and $7.7 million for the year.
Why It Matters
Sensus Healthcare's financial results reveal a revenue increase but ongoing losses, indicating growth potential tempered by profitability challenges, which could influence investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Sensus Healthcare (Nasdaq: SRTS) will report its Q4 and full year 2025 financial results on February 12, 2026, with a conference call scheduled for 4:30 p.m. ET.
Why It Matters
Sensus Healthcare's upcoming financial results and management call could impact stock performance, providing insights into growth, profitability, and future strategy.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About SRTS Stock
What is Sensus Healthcare Inc.'s (SRTS) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Sensus Healthcare Inc. (SRTS) has a median price target of $6.75. The highest price target is $8.00 and the lowest is $6.00.
Is SRTS stock a good investment in 2026?
According to current analyst ratings, SRTS has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.44. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SRTS stock?
Wall Street analysts predict SRTS stock could reach $6.75 in the next 12 months. This represents a 52.0% increase from the current price of $4.44. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Sensus Healthcare Inc.'s business model?
Sensus Healthcare generates revenue by selling its mobile superficial radiation therapy systems, such as the SRT-100, to dermatologists, oncologists, and healthcare facilities. By focusing on non-surgical treatments for conditions like non-melanoma skin cancers and keloids, the company positions itself in a niche market that prioritizes patient comfort and reduced recovery times.
What is the highest forecasted price for SRTS Sensus Healthcare Inc.?
The highest price target for SRTS is $8.00 from Yi Chen at HC Wainwright & Co., which represents a 80.2% increase from the current price of $4.44.
What is the lowest forecasted price for SRTS Sensus Healthcare Inc.?
The lowest price target for SRTS is $6.00 from Anthony Vendetti at Maxim Group, which represents a 35.1% increase from the current price of $4.44.
What is the overall SRTS consensus from analysts for Sensus Healthcare Inc.?
The overall analyst consensus for SRTS is bullish. Out of 5 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $6.75.
How accurate are SRTS stock price projections?
Stock price projections, including those for Sensus Healthcare Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 17, 2026 12:13 PM UTC